Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
出版年份 2022 全文链接
标题
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
作者
关键词
-
出版物
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 20, Issue 6, Pages 1400-1411
出版商
Wiley
发表日期
2022-03-15
DOI
10.1111/jth.15700
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study
- (2022) Dagmar Kubitza et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
- (2021) Dirk Thomas et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Abelacimab for Prevention of Venous Thromboembolism
- (2021) Peter Verhamme et al. NEW ENGLAND JOURNAL OF MEDICINE
- First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
- (2021) Vidya Perera et al. CTS-Clinical and Translational Science
- Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
- (2021) B. Alexander Yi et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
- (2021) Pancras C. Wong et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Milvexian for the Prevention of Venous Thromboembolism
- (2021) Jeffrey I. Weitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty
- (2020) Jeffrey I. Weitz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rivaroxaban in Peripheral Artery Disease after Revascularization
- (2020) Marc P. Bonaca et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
- (2019) Alexander W. Koch et al. BLOOD
- Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI
- (2019) Martina Schaefer et al. JOURNAL OF MOLECULAR BIOLOGY
- Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome
- (2018) Safi U. Khan et al. AMERICAN JOURNAL OF CARDIOLOGY
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis
- (2017) Jeffrey I. Weitz et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events
- (2016) Meir Preis et al. BLOOD
- Animal Models of Thrombosis From Zebrafish to Nonhuman Primates
- (2016) Pudur Jagadeeswaran et al. CIRCULATION RESEARCH
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
- (2015) Harry R. Büller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits
- (2014) Jonathan W. Yau et al. BLOOD
- Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys
- (2012) H. S. Younis et al. BLOOD
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo
- (2010) Q. Cheng et al. BLOOD
- Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
- (2010) H. Zhang et al. BLOOD
- Structure and function of factor XI
- (2010) J. Emsley et al. BLOOD
- Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI
- (2008) E. I. Tucker et al. BLOOD
- Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
- (2008) O. Salomon et al. BLOOD
- Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits
- (2008) P. C. WONG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started